Literature DB >> 2579961

Superinduction by cycloheximide of mitogen-induced secreted proteins produced by Balb/c 3T3 cells.

R T Hamilton, M Nilsen-Hamilton, G Adams.   

Abstract

We describe here some of the characteristics of the regulation of a group of secretory proteins whose secreted levels rise within 2-4 h of adding fibroblast growth factor (FGF), epidermal growth factor (EGF), or serum to quiescent Balb/c 3T3 cells. The levels of these secretory proteins are regulated similarly to the interferons. When cycloheximide is present during the induction period, the amounts of [35S]methionine incorporated into five of these proteins that we have called "superinducible proteins" (SIPs) is increased 2-5-fold. Superinduction of the SIPs is seen also in response to polyribol-polyriboC, the classical inducer of interferons. None of the SIPs, however, are immuno-precipitated by anti-beta-interferon antibody. Induction and superinduction of the SIPs is inhibited by actinomycin D. Superinduction occurs at concentrations of cycloheximide that inhibit protein synthesis by at least 85%. The SIPs are not major intracellular proteins; they are barely detectable in cellular fractions. Their induction is, however, correlated with the ability of the polypeptide growth factor to stimulate DNA synthesis; EGF, FGF, and serum induce the SIPs, whereas insulin does not, and insulin alone weakly stimulates DNA synthesis in these cells. Because FGF, EGF, and serum cause the SIPs to be produced at concentrations of cycloheximide that inhibit 85% of bulk protein and DNA synthesis, it follows that the SIPs are produced directly from the action of the growth factor and not as a consequence of increased growth. Although probably not interferons, in analogy to the lymphokines, the SIPs could be a set of autocrine or paracrine factors that rapidly convey the growth or differentiation signal between cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2579961     DOI: 10.1002/jcp.1041230208

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  8 in total

1.  Posttranscriptional control of human gamma interferon gene expression in transfected mouse fibroblasts.

Authors:  H A Young; L Varesio; P Hwu
Journal:  Mol Cell Biol       Date:  1986-06       Impact factor: 4.272

2.  Inducible release of an endothelial cell-specific protein.

Authors:  C W Carson; G G Hunder; K L Kaplan; C M Johnson
Journal:  Am J Pathol       Date:  1991-07       Impact factor: 4.307

3.  Apoptosis of serum-free C2.8 mouse embryo hepatocytic cells caused by hepatocyte growth factor deprivation.

Authors:  R P Revoltella; F Borney; B Dal Canto; C M D'Urso
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 4.  Shaping future strategies for the pharmacological control of tumor cell metastases.

Authors:  R G Greig; D L Trainer
Journal:  Cancer Metastasis Rev       Date:  1986       Impact factor: 9.264

5.  Evidence that the functional beta-actin gene is single copy in most mice and is associated with 5' sequences capable of conferring serum- and cycloheximide-dependent regulation.

Authors:  P K Elder; C L French; M Subramaniam; L J Schmidt; M J Getz
Journal:  Mol Cell Biol       Date:  1988-01       Impact factor: 4.272

6.  Vanadate-induced gene expression in mouse C127 cells: roles of oxygen derived active species.

Authors:  X Yin; A J Davison; S S Tsang
Journal:  Mol Cell Biochem       Date:  1992-09-22       Impact factor: 3.396

7.  The Lipocalin2 Gene is Regulated in Mammary Epithelial Cells by NFκB and C/EBP In Response to Mycoplasma.

Authors:  Wei Zhao; Lee Bendickson; Marit Nilsen-Hamilton
Journal:  Sci Rep       Date:  2020-05-06       Impact factor: 4.379

Review 8.  The role of lipocalin-2 in age-related macular degeneration (AMD).

Authors:  Sayan Ghosh; Nadezda Stepicheva; Meysam Yazdankhah; Peng Shang; Alan M Watson; Stacey Hose; Haitao Liu; Joseph Weiss; J Samuel Zigler; Mallika Valapala; Simon C Watkins; Debasish Sinha
Journal:  Cell Mol Life Sci       Date:  2020-01-04       Impact factor: 9.261

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.